Relmada Therapeutics Inc (RLMD)

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form PRE 14A - Other preliminary proxy statements

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Relmada Therapeutics shares jump 25% after promising bladder cancer trial results

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) climbed 25% on Monday after the company released 12-month interim results from its Phase 2...